Business
ClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023: ClearPoint Maestro® Brain Model and ClearPoint Prism™ Neuro Laser Therapy System
Solutions from ClearPoint portfolio, including SmartFlow cannula, Maestro and ClearPoint Neuro Navigation will be featured in abstracts and training programs
About this update from Clearpoint Neuro Inc.
[{"type":"text","content":"Solutions from ClearPoint portfolio, including SmartFlow cannula, Maestro and ClearPoint Neuro Navigation will be featured in abstracts and training programs throughout the meeting\nSOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will exhibit at the 2023 American Association of Neurological Surgeons (AANS) Annual Meeting being held in Los Angeles, CA from April 21 to April 23. The ClearPoint Maestro Brain Model will be shown at AANS for the first time since its Limited Market Release. Maestro is designed to enable highly accurate ClearPoint interventions under MRI guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning. The software, which was originally licensed in 2021 from Philips, a global leader in health technology, gained FDA clearance in 2022. Recent announcements related to Maestro include an extension of the Philips agreement to include fully automatic subnuclei segmentation for deep brain stimulation procedures, as well as a partnership with NE Scientific to integrate a gene therapy infusion tool into the model. Attendees who visit the booth (#1229) will experience hands-on how Maestro can assist neurosurgeons with targeting, and ClearPoint’s pharmaceutical partners with volume calculations for drug delivery trials. The software is currently installed at select institutions in the United States. The Company will also showcase the ClearPoint Prism Neuro Laser Therapy System, currently in Limited Market Release in the United States, and part of an ongoing prospective clinical trial for Glioblastoma in Europe. The system comprises a clinical solution combining the ClearPoint navigation platform, the laser technology from CLS, and a thermal ablation monitoring software called Thermoguide™ from Image Guided Therapy (IGT - Bordeaux, France). In 2022, CLS received FDA clearance for the ClearPoint Prism Neuro Laser Therapy System. Visitors to the booth will walk through ClearPoint’s novel streamlined workflow for laser interstitial thermal therapy (LiTT) including an efficient one-room solution that has helped neurosurgeons accurately place laser fibers to treat brain tumors, radiation necro...